Results of Operations and Financial Condition. Vericel Corporation (the “Company”) will participate in the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco, California, which is being held on Wednesday, January 14, 2026, at 11:15 a.m. Pacific Time. In connection with its participation in the conference, on January 13, 2026, the Company issued a press release, which includes estimates of operating and financial results, including its estimated, preliminary and unaudited full-yea…

The provided text is only the standard Item 5.02 header and introductory phrase, containing no specific details about a person, role, or action to classify.

Regulation FD Disclosure The United States government recently announced a broad range of tariffs on foreign goods imported into the U.S., with certain nations and regions responding with retaliatory tariffs on U.S. goods. Vericel Corporation (the “Company”) anticipates minimal impact on its business and operations from these tariffs, or future tariffs on pharmaceuticals that may be announced. All of the Company’s operations are located in the U.S. and 100% of the Company’s revenue in 2025, a…

Results of Operations and Financial Condition. In connection with its participation in the 43 rd Annual J.P. Morgan Healthcare Conference, on January 14, 2025, Vericel Corporation (the “Company”) issued a press release and updated its corporate presentation, both of which include estimates of operating and financial results as of and for the year ended December 31, 2024. The Company’s corporate presentation includes additional updates regarding its business. Because the Company’s financial st…

Other Events On August 26, 2024, Vericel Corporation issued a press release titled “Vericel Announces FDA Approval and Commercial Availability of MACI Arthro.” A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Other Events On August 15, 2024, Vericel Corporation issued a press release titled “Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns.” A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.